Compare Novo Nordisk A/S (NVO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Zoetis Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Novo Nordisk A/S is far larger — about 6.9× Zoetis Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | ZTS | |
|---|---|---|
Market Cap | $220.53B | $31.95B |
Sector | Health | Health |
52-Week High | $71.70 | $156.76 |
52-Week Low | $35.29 | $71.91 |
Enterprise Value | $239.49B | $39.24B |
Dividend Yield | 3.63% | 2.78% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
